Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Macy's Stock Is Soaring Today

By Rich Duprey - Nov 23, 2020 at 11:24AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A string of positive developments is lifting the retailer well beyond its peers.

What happened

Shares of Macy's ( M -3.25% ) were soaring 13% higher in morning trading Monday as more good news on a COVID-19 vaccine was released.

So what

AstraZeneca and Oxford University reported the vaccine they're working on was up to 90% effective without any serious side effects in a large trial, giving hope to investors there could be a recovery in the retail sector.

Macy's Herald Square store

Image source: Macy's.

On Friday, Pfizer asked the Food and Drug Administration for Emergency Use Authorization for its vaccine, which was found to be more than 90% effective in trials. The pharmaceutical giant said the vaccine could begin shipping as soon as the middle of next month.

Now what

Macy's stock has more than doubled from its March lows, but remains nearly 50% below where it started 2020 due to the ravages of the coronavirus pandemic. The health crisis also caused the cancellation of the Macy's Thanksgiving Day parade, a fixture of New York City and an iconic cultural event. It's only been canceled three times previously, all during the early 1940s due to a helium shortage caused by World War II.

The department store chain, however, was ailing well before the pandemic struck. The pandemic simply exacerbated the fault lines within its operation. 

Its stock got a boost last week, though, after the company reported better-than-expected earnings that were nonetheless disastrous. Investors began to feel Macy's will be able to survive the current climate, and with the vaccine developments, they're expecting its performance to dramatically improve.

 
This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Macy's, Inc. Stock Quote
Macy's, Inc.
M
$26.80 (-3.25%) $0.90
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$54.23 (-1.02%) $0.56
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$54.27 (2.32%) $1.23

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
624%
 
S&P 500 Returns
140%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/06/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.